Boston Partners purchased a new position in shares of Cascadian Therapeutics, Inc. (NASDAQ:CASC) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 380,143 shares of the biopharmaceutical company’s stock, valued at approximately $1,412,000. Boston Partners owned approximately 0.77% of Cascadian Therapeutics as of its most recent SEC filing.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Redmile Group LLC bought a new position in shares of Cascadian Therapeutics during the first quarter worth $16,860,000. BlueCrest Capital Management Ltd bought a new position in shares of Cascadian Therapeutics during the first quarter worth $122,000. Bank of America Corp DE raised its position in shares of Cascadian Therapeutics by 2,316.5% in the first quarter. Bank of America Corp DE now owns 37,528 shares of the biopharmaceutical company’s stock worth $155,000 after buying an additional 35,975 shares during the last quarter. Sabby Management LLC bought a new position in shares of Cascadian Therapeutics during the first quarter worth $669,000. Finally, Citadel Advisors LLC bought a new position in shares of Cascadian Therapeutics during the first quarter worth $142,000. 83.86% of the stock is currently owned by hedge funds and other institutional investors.
Cascadian Therapeutics, Inc. (NASDAQ CASC) opened at 3.59 on Thursday. The company’s market cap is $181.49 million. Cascadian Therapeutics, Inc. has a 52 week low of $3.18 and a 52 week high of $10.98. The firm has a 50-day moving average of $3.88 and a 200-day moving average of $3.99.
Cascadian Therapeutics (NASDAQ:CASC) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. During the same period in the previous year, the firm earned ($1.57) earnings per share. Equities analysts forecast that Cascadian Therapeutics, Inc. will post $5.02 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This news story was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be read at https://stocknewstimes.com/2017/08/24/boston-partners-takes-position-in-cascadian-therapeutics-inc-casc.html.
A number of brokerages have weighed in on CASC. Zacks Investment Research lowered shares of Cascadian Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, May 19th. ValuEngine lowered shares of Cascadian Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. Cantor Fitzgerald reaffirmed a “hold” rating and issued a $4.00 price target on shares of Cascadian Therapeutics in a research note on Wednesday, May 10th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Cascadian Therapeutics in a research note on Tuesday, May 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $6.17.
About Cascadian Therapeutics
Cascadian Therapeutics, Inc, formerly Oncothyreon Inc, is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company’s clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor.
Receive News & Ratings for Cascadian Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cascadian Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
